The effects of peroral administration of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance, single effet and chronic effect.

Not Applicable

• Conditions: Type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000031686
• Lead Sponsor: niversity of Juntendo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-03-16
• Study Completion: 2019-02-12
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Male
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

-type 1 diabetes mellitus -past history of taking Tofogliflozin -BMI range:>30 or <18.5 kg/m2 -liver dysfunction(AST,ALT => 51U/L,gamma-GTP over 101U/L) -renal dysfunction or eGFR level =< 60mL/min/1.73m2 -Patient with severe heart diseases (for example, heart failure and unstable angina) or the patient who occured myocardial infarction and anginal attack after 24 weeks ago from observation period -patient who had an apoplexy spasm (cerebral infarction and cerebral hemorrhage) within 24 weeks until agreement acquisition -patient with malignant tumor -patient with advanced diabetes complications (neuropathy , retinopathy and nephropathy) -patient of serious illness ketotic, a diabetic coma or the previous coma -Patient with the endocrine diseases for which treatment is insufficient for hormone replenishment method of treatment (for example,pituitary disease, thyroid disease and adrenal disease) -anemia beyond the degree of middle class (hemoglobin < 9.5g/dL) -drunkard(for example 1 daily mean sake, by 3 gou and beer, more than 3 flagons) -subjects judged unsuitable to the study from staff

Study & Design

• Study Type: Interventional
• Study Design: Not specified